© 2022 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
Policy Harmonization, Clarification Could Aid Biosimilar Uptake Efforts
Skylar Jeremias
September 23 2022
Realigning definitions and policies across regulatory agencies and developing a better understanding of how different stakeholders approach biosimilars could help get more patients and providers on board with using biosimilars, according to panelists at the DIA Biosimilars Conference.
Rituximab Biosimilars Prove Effective in Large B-Cell Lymphoma
Skylar Jeremias
July 14 2022
Abstracts from the European Hematology Association Congress 2022 confirmed comparable safety and effectiveness profiles between 2 rituximab biosimilars and the reference product (Rituxan) in patients with large B-cell lymphoma.
ASCO Studies Assess Biosimilar Substitution, Adoption in Oncology Practices
Skylar Jeremias
June 16 2022
Abstracts from the American Society of Clinical Oncology (ASCO) annual meeting took a look at the impact biosimilar substitution and increased biosimilar adoption had on spending within practices participating in value-based payment models and the Oncology Care Model.
Ryan Haumschild, PharmD, Advises Practices, Health Systems to Prep for Interchangeable Biosimilars
Skylar Jeremias
June 5 2022
Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives an overview of what practices and health systems need to prepare for as more interchangeable biosimilars enter the US market.
Celltrion’s Infliximab Biobetter Shows Significant Clinical Improvements Over Original Biosimilar Version
Skylar Jeremias
June 4 2022
Results from the European Congress of Rheumatology’s annual meeting revealed that Celltrion’s Remsima SC, a subcutaneous biobetter infliximab product, produced better clinical outcomes compared with the original Remsima, an infliximab biosimilar delivered intravenously.
Dr Sonia Oskouei Predicts How Bevacizumab Use Will Evolve in Ophthalmology
Skylar Jeremias
May 22 2022
The use of bevacizumab products for ophthalmic conditions will continue to evolve as the market grows. However, off-label usage will likely be the norm, according to Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, at Asembia’s Specialty Pharmacy Summit.
Dr Eric Tichy Calls for Government Officials to Realign Incentives in Favor of Biosimilars
Skylar Jeremias
May 18 2022
Altering reimbursement procedures needs to become a bigger priority for government officials to incentivize biosimilar utilization, according to Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System.